SPI Infoamtion

1.1 List of Tables
1.2 List of Figures

2 Introduction and Overview
2.1 GlobalData Report Guidance

3 Major Cardiovascular Indications Approved for Drug Eluting Balloons (DEB): Disease Pathophysiology, Etiology, and Epidemiology
3.1 In-stent Restenosis
3.1.1 Introduction
3.1.2 Pathophysiology
3.1.3 Etiology: Risk Factors for the Disease
3.2 In-Stent Restenosis Epidemiology: Global
3.2.1 Treatment Flow Model
3.3 In-stent Restenosis: Device Based Treatment Modalities and their Outcomes
3.4 Peripheral Vascular Disease: Overview and Pathophysiology
3.4.1 Introduction
3.5 Peripheral Vascular Disease Epidemiology: Global
3.5.1 Treatment Flow Model
3.6 Peripheral Vascular Disease: Device Based Treatment Modalities and their Outcomes

4 Global Drug Eluting Balloons Market : Market Characterization
4.1 Global Drug Eluting Balloons Market, Revenue ($m), 2007-2016
4.2 Global Drug Eluting Balloons Market, Volume (Units), 2007-2016
4.3 Drug Eluting Balloons, Market Dynamics
4.3.1 Market Drivers
4.3.2 Market Restraints
4.4 Drug Eluting Balloons: Unmet Need and Opportunities
4.4.1 Unmet Need
4.4.2 Opportunities

5 Global Drug Eluting Balloons (DEB) Market: Cross-Country Market Analysis and Forecasts
5.1 Global Drug Eluting Balloons Market: Cross-Country Analysis
5.2 Drug Eluting Balloons (DEB), Revenue, By Country, 2007 - 2016
5.2.1 Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 - 2016
5.2.2 Drug Eluting Balloons Market, France, Revenue ($m), 2007 - 2016
5.2.3 Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
5.2.4 Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
5.2.5 Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
5.2.6 Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
5.2.7 Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
5.2.8 China Drug Eluting Balloons Market, Revenue ($m), 2009 - 2016

6 Global Drug Eluting Balloons Market: Company Share Analysis and Key Market Participants
6.1 Global Drug Eluting Balloons Market, Company Share (%), 2009
6.2 B Braun
6.2.1 Overview
6.2.2 Drug Eluting Balloons Portfolio
6.3 Eurocor
6.3.1 Overview
6.4 Invatec
6.4.1 Overview
6.4.2 Drug Eluting Balloons Portfolio
6.5 Aachen Resonance GmbH
6.5.1 Overview
6.5.2 Drug Eluting Balloons Portfolio

7 Global Drug Eluting Balloons Market: Key Marketed Products
7.1 SeQuent Please
7.1.1 Product Overview and Description
7.1.2 Key Technology
7.1.3 Clinical Study Results
7.2 DIOR Paclitaxel-Eluting Coronary Balloon Catheter
7.2.1 Product Overview and Description
7.2.2 Key Technology
7.2.3 Clinical Study Results
7.3 Elutax
7.3.1 Product Overview and Description
7.3.2 Key Technology
7.3.3 Clinical Study Results
7.4 IN.PACT Amphirion Paclitaxel Eluting Balloon Catheter
7.4.1 Product Description
7.4.2 Key Technology
7.4.3 Clinical Study Results

8 Global Drug Eluting Balloons Market: Strategic Pipeline Assessment
8.1 Pipeline Technology Assessment
8.1.1 Pipeline Technology Assessment for Drug Eluting Balloons by Development Stage
8.1.2 Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need
8.1.3 Novel Pipeline Technology Assessment for Drug Eluting Balloons
8.2 Drug Eluting Balloons: List of Pipeline Products
8.3 Profiles of Promising Products under Clinical Development
8.3.1 Lutonix
8.3.2 Advance 18PTX
8.3.3 Cotavance
8.3.4 Genesis DESA Catheter
8.3.5 Drug-Eluting PTA Balloon Catheter
8.3.6 Drug-Eluting Balloon
8.3.7 PTCA Balloon Genistein-coated balloon catheter

9 Global Drug Eluting Balloons Market: Strategic Deals Analysis
9.1 Key Acquisitions
9.1.1 Medtronic Acquired Invatec
9.1.2 MEDRAD Completes Acquisition Of Possis Medical
9.1.3 Opto Circuits Acquired Eurocor
9.2 Key Partnerships
9.2.1 Maxcor entered a strategic agreement with Micell Technologies to develop new balloon and stent system
9.2.2 Eurocor enters distribution agreement with Goodman for entering Japan market in 2007
9.2.3 MEDRAD Enters Into Licensing Agreement With B. Braun Melsungen
9.2.4 DSM Biomedical and Caliber Therapeutics form partnership to develop a drug-delivery balloon catheter to treat atherosclerosis.
9.2.5 Aachen Resonance enters into a distribution agreement with Biotronik to distribute Elutax in Europe

10 Appendix
10.1 Definitions
10.1.1 Interventional Cardiology
10.1.2 Peripheral Vascular Devices
10.1.3 Drug Eluting Balloons
10.2 Acronyms
10.3 Research Methodology
10.4 Secondary Research
10.5 Primary Research
10.6 Models
10.7 Forecasts
10.8 Expert Panels
10.9 GlobalData Consulting
10.10 Contact Us
10.11 Disclaimer

List of Figures
Figure 1: Treatment Flow Model, Drug Eluting Balloons for Treatment of In-stent restenosis, 2009
Figure 2: Device Based Treatment Modalities for In-Stent Restenosis
Figure 3: Treatment Flow Model, Drug Eluting Balloons for Treatment of Peripheral Artery Disease, 2009
Figure 4: Device Based Treatment Modalities for Peripheral Vascular Disease
Figure 5: Drug Eluting Balloons Market, Global, Revenue ($m), 2007-2016
Figure 6: Drug Eluting Balloons Market, Global, Volume (Units), 2007 - 2016
Figure 7: Unmet Need and Opportunities Analysis for Drug Eluting Balloons, 2010
Figure 8: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison, ($m), 2009
Figure 9: Drug Eluting Balloons (DEB) Market, Germany, Revenue ($m), 2007 - 2016
Figure 10: Drug Eluting Balloons Market, France, Revenue ($m) , 2007 - 2016
Figure 11: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
Figure 12: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
Figure 13: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
Figure 14: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
Figure 15: Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
Figure 16: Drug Eluting Balloons Market, China, Revenue ($m), 2009 - 2016
Figure 17: Drug Eluting Balloons Market, Global, Company Share (%), 2009
Figure 18: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, Europe
Figure 19: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, US
Figure 20: Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need
Figure 21: Novel Pipeline Technology Assessment for Drug Eluting Balloons
Figure 22: GlobalData Methodology

List of Tables
Table 1: Drug Eluting Balloons Market, Global, Revenue($m), 2007-2016
Table 2: Drug Eluting Balloons Market, Global, Volume (Units), 2007 - 2016
Table 3: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison, ($m), 2009
Table 4: Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 - 2016
Table 5: Drug Eluting Balloons Market, France, Revenue ($m), 2007 - 2016
Table 6: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 - 2016
Table 7: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 - 2016
Table 8: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 - 2016
Table 9: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 - 2016
Table 10: Drug Eluting Balloons Market, India, Revenue ($m), 2009 - 2016
Table 11: Drug Eluting Balloons Market, China, Revenue ($m), 2009 - 2016
Table 12: Drug Eluting Balloons Market, Global, Key Company Shares (%), 2009
Table 13: B Braun, DEB Pipeline Products
Table 14: Eurocor, DEB Pipeline Products
Table 15: Invatec, DEB Pipeline Products
Table 16: Aachen Resonance, Pipeline Products
Table 17: List of Pipeline Products, Drug Eluting Balloons
Table 18: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, European Registry Investigating The Lutonix Paclitaxel-Coated Balloon For The Treatment Of In-Stent Restenosis Within Bare-Metal Stents
Table 19: Lutonix Balloon angioplasty catheter - An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.
Table 20: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting.
Table 21: Advance 18 PTX Balloon Catheter - Advance 18PTX Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon